Cite
HARVARD Citation
Spoorendonk, J. et al. (2021). Clinical implications and cost-effectiveness analysis of rivaroxaban in patients with coronary artery disease or peripheral arterial disease in the Netherlands. Journal of medical economics. pp. 1231-1239. [Online].